Skip to Content Facebook Feature Image

Touch the Future: Hanvon Unveils the World's First EMC-Touch Chip & Penstar Brand at CES 2025

Business

Touch the Future: Hanvon Unveils the World's First EMC-Touch Chip & Penstar Brand at CES 2025
Business

Business

Touch the Future: Hanvon Unveils the World's First EMC-Touch Chip & Penstar Brand at CES 2025

2025-01-09 11:14 Last Updated At:11:35

LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- Hanvon Technology, a pioneer in China's artificial intelligence industry, made a significant splash at the CES 2025 Global Consumer Electronics Show, held at the Las Vegas Convention Center. Under the theme "Touch the Future," Hanvon showcased a range of innovative technologies and products, including the world's first EMC-Touch chip, HW0888, the Penstar digital notebook brand, biomimetic flying robots, digital signature, input method and OCR solutions. The event highlighted Hanvon's key original technologies and its extensive industrial layout.

EMC-Touch Chip: Touch the Future Together
Since its founding in 1993, Hanvon has been deeply involved in the field of electromagnetic touch technology and is one of only two companies globally holding wireless passive electromagnetic patents. In 2010, Hanvon expanded into the capacitive touch field. Combining 30 years of expertise in electromagnetic technology with 15 years in capacitive touch technology, Hanvon has innovatively introduced the world's first EMC-Touch chip, HW0888. This chip, along with a single layer of sensors, perfectly realizes the EMC solution, supporting both passive electromagnetic pens and capacitive touch. It features 8192 levels of pressure sensitivity and multi-finger touch functionality.

Penstar: Redefining the Digital Notebook Market
To tap into the large and steadily growing global market, Hanvon has developed a new brand strategy for Penstar, actively expanding into overseas e-commerce channels. The Penstar eNote digital notebook opened for sales in the North American market in August 2024 and has quickly gained popularity among users in North America.

The Penstar eNote is equipped with Hanvon's revolutionary PureViewâ„¢ ePaper screen technology, which eliminates accidental touches and enhances screen clarity. Since its launch, it has received widespread acclaim. Penstar's debut at CES marks the accelerated global expansion of Hanvon's digital notebook offerings, both online and offline, and highlights the company's ambition in the global digital notebook market.

The New GoGoBird 3010: Soaring Globally
Hanvon's GoGoBird is the world's first commercialized autonomous flying biomimetic robot with flapping wings. Since its launch in 2019, it has quickly gained traction in markets across North America, Australia, Europe, Japan, and South Korea. The GoGoBird 3010, also known as "Golden Eagle," is Hanvon's latest model. It integrates biomimetic flight, intelligent sensing, and AI technology, offering features such as autonomous obstacle avoidance and high-definition real-time image transmission.

Profound Technological Accumulation and Deep Industry Expertise
At CES, Hanvon also showcased industry-leading solutions in digital signatures, input methods, and OCR, promoting global digital sustainable development.

Hanvon's input method, integrated with Hanvon's handwriting recognition, supports multiple languages with high recognition accuracy, low resource consumption, and high security. This method is closely integrated with in-vehicle applications, optimizing input efficiency based on specific scenarios, and is customized for multi-screen input, voice recognition, and multi-terminal screen responses, enabling a more comfortable and secure human-vehicle interaction.

With more than 20 years of experience in OCR, Hanvon has solved world-class challenges, such as recognizing freehand manuscripts, achieving a handwriting recognition rate of over 95%. Hanvon's OCR solution has been successfully applied in scenarios such as financial bills, cards and certificates, vehicle driving licenses, reimbursement vouchers, and batch data recognition, helping businesses reduce costs and improve efficiency.

Leading AI Innovation and Industrial Development
Hanvon has long been at the forefront of artificial intelligence innovation and industrial development. The introduction of the world's first EMC-Touch chip, the Penstar digital notebook, GoGoBird, and other groundbreaking applications at CES demonstrates Hanvon's leadership in AI-driven interactions.

"Hanvon will continue to prioritize original innovation, striving to fulfill the mission of 'machines understanding you better.' Together, we will touch the future in this new era of artificial intelligence," said a Hanvon spokesperson.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Touch the Future: Hanvon Unveils the World's First EMC-Touch Chip & Penstar Brand at CES 2025

Touch the Future: Hanvon Unveils the World's First EMC-Touch Chip & Penstar Brand at CES 2025

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles